WO2009002811A3 - Compositions thérapeutique plaquette et procédés - Google Patents

Compositions thérapeutique plaquette et procédés Download PDF

Info

Publication number
WO2009002811A3
WO2009002811A3 PCT/US2008/067592 US2008067592W WO2009002811A3 WO 2009002811 A3 WO2009002811 A3 WO 2009002811A3 US 2008067592 W US2008067592 W US 2008067592W WO 2009002811 A3 WO2009002811 A3 WO 2009002811A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
angiogenesis
platelets
regulating
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2008/067592
Other languages
English (en)
Other versions
WO2009002811A2 (fr
Inventor
Dennis Orgill
Giorgio Pietramaggiori
Giannoula Klement
David Cervi
Judah Folkman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Brigham and Womens Hospital Inc
Boston Childrens Hospital
Original Assignee
Brigham and Womens Hospital Inc
Boston Childrens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham and Womens Hospital Inc, Boston Childrens Hospital filed Critical Brigham and Womens Hospital Inc
Publication of WO2009002811A2 publication Critical patent/WO2009002811A2/fr
Publication of WO2009002811A3 publication Critical patent/WO2009002811A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/19—Platelets; Megacaryocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0057—Ingredients of undetermined constitution or reaction products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0061—Use of materials characterised by their function or physical properties
    • A61L26/0066—Medicaments; Biocides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0061—Use of materials characterised by their function or physical properties
    • A61L26/008—Hydrogels or hydrocolloids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/412—Tissue-regenerating or healing or proliferative agents
    • A61L2300/414—Growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/64—Animal cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Materials Engineering (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des procédés et des compositions destinés à l'administration thérapeutique de facteurs de régulation de l'angiogenèse à des sites in vivo les nécessitant. Les procédés et les compositions portent de manière générale sur l'utilisation de plaquettes portant un ou plusieurs facteurs de régulation exogènes de l'angiogenèse. Selon un aspect, l'invention concerne des procédés d'administration d'un facteur de régulation de l'angiogenèse, le procédé consistant à mettre en contact un tissu avec une composition contenant des plaquettes isolées qui renferment un facteur de régulation exogène de l'angiogenèse. Les procédés peuvent notamment être utilisés pour accélérer la cicatrisation de plaies, ou, dans une variante, pour inhiber la croissance tumorale. Selon un autre aspect, l'invention concerne des compositions thérapeutiques à base de plaquettes et des trousses, les plaquettes portant un ou plusieurs facteurs de régulation exogènes de l'angiogenèse. L'invention concerne également des procédés permettant de moduler la libération de facteurs favorisant et inhibant l'angiogenèse par des plaquettes au moyen d'agonistes et/ou d'antagonistes de récepteurs de plaquette activés par des protéases, à savoir les récepteurs PAR-1 et PAR-4.
PCT/US2008/067592 2007-06-22 2008-06-20 Compositions thérapeutique plaquette et procédés Ceased WO2009002811A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US93692107P 2007-06-22 2007-06-22
US60/936,921 2007-06-22

Publications (2)

Publication Number Publication Date
WO2009002811A2 WO2009002811A2 (fr) 2008-12-31
WO2009002811A3 true WO2009002811A3 (fr) 2009-02-12

Family

ID=39930521

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/067592 Ceased WO2009002811A2 (fr) 2007-06-22 2008-06-20 Compositions thérapeutique plaquette et procédés

Country Status (1)

Country Link
WO (1) WO2009002811A2 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2982461T3 (es) 2008-09-16 2024-10-16 Mayo Found Medical Education & Res Composiciones que contienen contenido plaquetario
EP2903646A1 (fr) * 2012-10-04 2015-08-12 Genesys Research Institute Compositions de plaquettes et utilisations de celles-ci
WO2015109220A1 (fr) * 2014-01-17 2015-07-23 President And Fellows Of Harvard College Leurre plaquettaire et son utilisation
WO2015124570A1 (fr) * 2014-02-18 2015-08-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthodes et composition pharmaceutique pour le traitement de l'infection par le virus de la grippe a
US11891620B2 (en) * 2014-05-16 2024-02-06 Mayo Foundation For Medical Education And Research Cell culture media compositions for primary cells
MX2020007071A (es) 2018-01-05 2020-11-11 Platelet Biogenesis Inc Composiciones y metodos para producir megacariocitos.
EP3813853A4 (fr) 2018-06-29 2022-04-06 Platelet Biogenesis, Inc. Compositions pour l'administration de médicaments et leurs méthodes d'utilisation
TWI789724B (zh) * 2020-03-20 2023-01-11 台灣粒線體應用技術股份有限公司 粒線體用於治療及/或預防肌腱受損或其相關疾病之用途
WO2021231990A1 (fr) * 2020-05-15 2021-11-18 Platelet Biogenesis, Inc. Procédés et production améliorés de nouvelles plaquettes
CN119139532A (zh) * 2024-11-20 2024-12-17 昆明医科大学 一种海绵贴片及其制备方法与应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999066923A1 (fr) * 1998-06-22 1999-12-29 Autologous Wound Therapy, Inc. Cicatrisant pour blessures ameliore a l'aide de plaquettes enrichies
US20040001816A1 (en) * 1998-06-22 2004-01-01 Cytomedix, Inc. Enriched platelet wound healant

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999066923A1 (fr) * 1998-06-22 1999-12-29 Autologous Wound Therapy, Inc. Cicatrisant pour blessures ameliore a l'aide de plaquettes enrichies
US20040001816A1 (en) * 1998-06-22 2004-01-01 Cytomedix, Inc. Enriched platelet wound healant

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ITALIANO JOSEPH ET AL: "Blood platelets organize pro- and anti-angiogenic factors into separate, distinct alpha granules: Implications for the regulation of angiogenesis", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 108, no. 11, 16 November 2006 (2006-11-16), pages 120A - 121A(Abst, XP009108492, ISSN: 0006-4971 *
MA L. ET AL.: "Proteinase-activated recepors 1 and 4 counter-regulate endostatin and VEGF release from human platelets.", PNAS, vol. 102, no. 1, 4 January 2005 (2005-01-04), pages 216 - 220, XP002503736 *
PIETRAMAGGIORI G.: "Trehalose lyophilized platelets for wound healing.", WOUND REP. REG., vol. 15, April 2007 (2007-04-01), pages 213 - 220, XP002503737 *
SALGADO R ET AL: "Platelets and vascular endothelial growth factor (VEGF): A morphological and functional study", ANGIOGENESIS, KLUWER, DORDRECHT, NL, vol. 4, 1 January 2001 (2001-01-01), pages 37 - 43, XP002995368, ISSN: 0969-6970 *

Also Published As

Publication number Publication date
WO2009002811A2 (fr) 2008-12-31

Similar Documents

Publication Publication Date Title
HK1210422A1 (en) Compositions and methods for treating cutaneous scarring
MX2009010067A (es) Analogos de imidazolopirimidina y su uso como inhibidores de mtor y cinasa pi3.
WO2009149418A3 (fr) Nouvelles compositions pour l’administration in vivo d’agents arni
WO2010003120A3 (fr) Antagonistes des récepteurs de la prostaglandine d<sb>2</sb>
WO2009108720A3 (fr) Antagonistes des récepteurs d2 de la prostaglandine
WO2009108934A3 (fr) Ciments de phosphate de calcium injectables formulés avec des agents bioactifs et procédés de fabrication associés
WO2008063291A3 (fr) Ligands polypeptidiques ciblant le cartilage et procédés d'utilisation de ceux-ci
ATE545441T1 (de) Verfahren und vorrichtungen zur minimal invasiven abgabe von zellhaltigen fliessfähigen zusammensetzungen
WO2007112084A8 (fr) Procédé permettant de moduler la croissance de cellules souches hématopoïétiques
GB2460597A (en) N,N-disubstituted aminoalkylbiphenyl antagonists of prostaglandin D2 receptors
WO2010078538A3 (fr) Supports améliorés pour la distribution de microparticules à des tissus et fluides corporels
WO2012058673A3 (fr) Traitement et surveillance améliorés du cancer au moyen de vecteurs recombinants
WO2007038246A3 (fr) Compositions polymeres solides pour administration et methodes d'utilisation de celles-ci
WO2010054113A3 (fr) Antagonistes de cycloalkane[b]azaindole de récepteurs de la prostaglandine d2
WO2010057118A3 (fr) Antagonistes hétérocycliques des récepteurs de la prostaglandine d2
MY164730A (en) Aminoalcohol substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
CL2009000246A1 (es) Compuestos derivados de 1h-imidazo[4,5-b]piridin-2-ol; moduladores de la contraccion sarcomero; composicion farmaceutica que comprende; kit farmaceutico; y uso en el tratamiento de enfermedades neuromusculares, tales como atrofia, fatiga, claudicacion, en entre otras.
UA100526C2 (ru) Способ и композиция для обработки семян
WO2010028254A3 (fr) Inhibiteurs de tyrosine kinases de récepteur de facteur de croissance de type quinazoline substituée
WO2010077883A3 (fr) Antagonistes des récepteurs d'acide lysophosphatidique
EP4467160A3 (fr) Formulations liquides stabilisées et lyophilisées d'adamts13
WO2009102893A3 (fr) Composés diaryliques cycliques en tant qu'antagonistes de récepteurs de prostaglandine d<sb>2</sb>
WO2010068775A3 (fr) Antagonistes d'alcyne de récepteurs d'acide lysophosphatidique
WO2012092628A3 (fr) Patchs et méthodes d'administration transdermique d'agents destinés à traiter la perte de cheveux
WO2010085820A3 (fr) Composés tricycliques en tant qu'antagonistes des récepteurs d2 de la prostaglandine

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08771541

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08771541

Country of ref document: EP

Kind code of ref document: A2